W hile this will allow them a cost advantage, less competition in the US will enable them to raise product prices. While Mylan recently acquired Strides Arcolab's Bengaluru-based injectible manufacturing facility, Agila Specialities, others such as Teva and Watson are also reportedly eyeing buyouts in India. "In the absence of competition from Indian firms, foreign generic manufacturers will not only gain market share but get a bigger advantage by earning more margins on products by escalating prices. "As soon as the number of companies in a particular segment will reduce, the remaining players will get better negotiating powers," said a senior official with a leading pharmaceutical company.. ..